Cytokinetics (CYTK) Corporate presentation summary

Strategic vision and mission

• Aims to be the leading muscle-focused specialty biopharma company, improving patient lives through global access to innovative medicines by 2030.

• Mission centers on developing new medicines for cardiovascular and neuromuscular diseases with impaired muscle function.

• Goals include advancing two approved products across three indications and reaching over 100,000 patients globally.

Product portfolio and pipeline

• MYQORZO (aficamten) approved in the U.S., EU, and China for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

• Pipeline includes late-stage programs for non-obstructive HCM (nHCM), pediatric oHCM, heart failure with preserved ejection fraction (HFPEF), and heart failure with reduced ejection fraction (HFrEF).

• Investigational agents ulacamten and omecamtiv mecarbil are in Phase 2 and Phase 3 trials, respectively.

Clinical trial highlights

• SEQUOIA-HCM and MAPLE-HCM Phase 3 trials showed significant improvements in exercise capacity, symptoms, and cardiac biomarkers for aficamten.

• ACACIA-HCM Phase 3 trial in nHCM met dual primary endpoints, with robust improvements in functional capacity and quality of life.

• Integrated safety analysis across trials shows low incidence of serious adverse events and manageable safety profile for aficamten.